Cancel
Fate Therapeutics
Fate Therapeutics Employees
7 people indexed:
-
Barbara Hickingbottom, M.D., J.D.
Senior Vice President, Clinical Development
-
Bob Valamehr, Ph.D.
Chief Research & Development Officer
qz5.xn634nn0.j7.4@0n9qn8n686g927w6.qg9 Sign up to see emailq6w.4q6kk30g.z0.2@2w85036g4q659968.k46 Sign up to see email -
7b287.wz80.6.3@05qk60757414w21k.01v Sign up to see email
-
5y1yk2.vyq87@1nx4zvj7y21336yq.5nn Sign up to see email
-
Jerome Bressi, Ph.D.
Senior Vice President, Regulatory & Quality
78nx23.wx8wll.v7.q@690x2g623yyl0y0n.2gy Sign up to see email91wnn9.x4v8q5.86.1@4kxl27yvv60533y5.n70 Sign up to see email -
Jim Beitel
Senior Vice President, Corporate Development
gvg.8g97w9@z23qdv067dgkvv3w.929 Sign up to see emaily0d.zwnkg5@2y37gx36689x1852.d2g Sign up to see email -
3x49v.x362xyd@zz92jv10n7zb64y2.nz5 Sign up to see email
Fate Therapeutics Company Information
Fate Therapeutics, based in San Diego, California, specializes in the development and clinical production of iPSC-derived cell product candidates for cancer treatment. The company operates two cGMP-compliant manufacturing facilities, both licensed by the State of California, Department of Health Services, Food and Drug Branch for drug manufacturing. In 2022, Fate Therapeutics expanded its manufacturing capabilities to its new corporate headquarters to support all phases of clinical development and initial commercialization efforts. The company’s research focuses on iPSC-derived NK cell product candidates and collaborates with ONO Pharmaceutical to develop CAR-T cell therapies for solid tumors. Additionally, Fate Therapeutics is engaged in research collaborations with the University of Minnesota, Memorial Sloan Kettering Cancer Center, and Oslo University Hospital, focusing on various aspects of cell biology and immunotherapies. The company also holds a significant intellectual property portfolio with over 400 issued patents and 450 pending applications related to iPSC technology.
Report inaccurate information
Report inaccurate information
